CRISPR Therapeutics (NASDAQ:CRSP) traded higher in the premarket on Thursday after J.P. Morgan initiated its coverage with an Overweight recommendation, noting how the company stands out in the gene ...

Beyond healthcare, gene editing is unlocking vast new opportunities across diverse industries. Every technological breakthrough heralds a new set of applications and prospects, leading to significant ...

Ottawa, Sept. 01, 2025 (GLOBE NEWSWIRE) -- According to Precedence Research, the global CRISPR-based gene editing market size was estimated at USD 3.06 billion in 2024. It is predicted to surpass ...

Despite pipeline setbacks and slow CASGEVY rollout, future revenue acceleration and expansion into cardiovascular and autoimmune diseases offer significant long-term growth opportunities. CRISPR ...

CRISPR Therapeutics' only approved product may experience increased demand. The biotech could also see significant clinical progress with some key candidates. Although the stock might jump on positive ...

CRISPR gene editing machinery holds the potential to transform the treatment of numerous diseases, but it requires effective delivery systems to get into tissues and ...

CRISPR Therapeutics is a gene editing specialist. The company's only approved product, Casgevy -- which it commercializes in partnership with Vertex Pharmaceuticals-- has not yet generated much ...

CRISPR may be a powerful technology for gene editing, but the system existed in bacteria long before scientists began using it. For billions of years, CRISPR has acted as a natural immune system in ...

Crispr Therapeutics remains highly volatile, disconnected from near-term fundamentals, yet I see long-term value far above current levels. CRSP's business progress is slow, with pipeline milestones ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...